0OO9 Stock Overview
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Fresenius SE & Co. KGaA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €26.63 |
| 52 Week High | €31.23 |
| 52 Week Low | €23.94 |
| Beta | 1.08 |
| 1 Month Change | 5.86% |
| 3 Month Change | 1.48% |
| 1 Year Change | 5.52% |
| 3 Year Change | -33.12% |
| 5 Year Change | -46.23% |
| Change since IPO | 45.12% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0OO9 | GB Healthcare | GB Market | |
|---|---|---|---|
| 7D | 5.3% | 0.1% | -1.4% |
| 1Y | 5.5% | -28.3% | -2.4% |
Return vs Industry: 0OO9 exceeded the UK Healthcare industry which returned -28.3% over the past year.
Return vs Market: 0OO9 exceeded the UK Market which returned -2.4% over the past year.
Price Volatility
| 0OO9 volatility | |
|---|---|
| 0OO9 Average Weekly Movement | 3.5% |
| Healthcare Industry Average Movement | 7.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.5% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0OO9 has not had significant price volatility in the past 3 months.
Volatility Over Time: 0OO9's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1912 | 193,865 | Michael Sen | www.fresenius.com |
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.
Fresenius SE & Co. KGaA Fundamentals Summary
| 0OO9 fundamental statistics | |
|---|---|
| Market cap | €15.01b |
| Earnings (TTM) | €353.00m |
| Revenue (TTM) | €22.30b |
42.5x
P/E Ratio0.7x
P/S RatioIs 0OO9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0OO9 income statement (TTM) | |
|---|---|
| Revenue | €22.30b |
| Cost of Revenue | €17.24b |
| Gross Profit | €5.06b |
| Other Expenses | €4.71b |
| Earnings | €353.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 08, 2024
| Earnings per share (EPS) | 0.63 |
| Gross Margin | 22.68% |
| Net Profit Margin | 1.58% |
| Debt/Equity Ratio | 70.4% |
How did 0OO9 perform over the long term?
See historical performance and comparison